Quick Answer
Lyell Immunopharma, Inc. reported Operating Income of -$269.40 million for fiscal year 2025.
Lyell Immunopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$269.40M | +24.9% |
| 2024 | -$358.75M | -45.2% |
| 2023 | -$247.01M | -32.0% |
| 2022 | -$187.06M | +12.9% |
| 2021 | -$214.78M | -1.3% |
| 2020 | -$211.94M | -107.6% |
| 2019 | -$102.09M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$37.25M | +26.2% | +21.0% |
| June 30, 2025 | -$47.14M | +8.5% | +17.8% |
| March 31, 2025 | -$57.37M | -3.2% | -13.6% |
| September 30, 2024 | -$50.51M | +14.5% | +2.0% |
| June 30, 2024 | -$51.53M | +21.8% | +7.3% |
| March 31, 2024 | -$55.58M | +11.2% | +5.9% |
| September 30, 2023 | -$59.04M | +11.1% | +10.4% |
| June 30, 2023 | -$65.91M | -76.9% | -5.4% |
- Lyell Immunopharma, Inc. showed an increase of +24.9% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Lyell Immunopharma, Inc.’s operating income has declined by 163.9% (from -$102.09 million to -$269.40 million).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: